Supernus Pharmaceuticals, Inc.
Clinical trials sponsored by Supernus Pharmaceuticals, Inc., explained in plain language.
-
Huntington's drug safety trial ends early: what we know
Disease control TerminatedThis study looked at the long-term safety of an experimental drug called SAGE-718 for people with Huntington's disease. It was a phase 3 trial that planned to enroll 153 participants but was terminated early. The main goal was to track side effects and changes in vital signs, lab…
Phase: PHASE3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Migraine prevention drug for kids falls short in early trial
Prevention TerminatedThis study aimed to see if the drug SPN-538 could prevent migraines in children aged 6 to 11. It included 26 children who had migraines for at least 6 months. The study was stopped early, so results are limited.
Phase: PHASE4 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Prevention
Last updated May 11, 2026 20:38 UTC